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EDITORIAL

Pharmacotherapy: Drugs, the Kidney,
and Hippocrates

H

ippocrates first noted that the urinary
output varied with exogenous intake of
food and imbibition of liquids.1 However, despite his insight, Hippocrates could exposit
neither the role of normal kidneys in drug metabolism and disposition nor the consequent
changes in pharmacokinetics and pharmacodynamics of medicinals that accrued in the
face of kidney failure.2 Certainly, he could
not appreciate the fundamental concepts of renal drug elimination including (a) glomerular
filtration, (b) active tubular secretion, and (c)
passive reabsorption. Furthermore, this father
of clinical nephrology neither possessed the
investigative tools to elucidate the metabolic
matrimony between the liver and kidney that
was required of some drugs nor did he understand that drug elimination was more efficiently carried out by the active, organic
anion/cation tubular-secretory components
of the nephron than by its glomerular counterpart. In fact, the molecular tools required to
elucidate the mechanisms of xenobiotic disposal lay centuries ahead and have been developed only recently.
The field of renal pharmacology has been
defined by the careers of a relative few. These
visionaries appreciated early on that highlevel cognizance of pharmacology in chronic
kidney disease was a prerequisite to the delivery of high quality medical care. They comprehended that one important consequence of
increasing kidney failure was an attendant
and escalating exposure to medications, per
se constant drugging with continual exposure
to nephrotoxic agents or drugs that required

renal metabolism. The exacerbation of these
potentially hazardous scenarios with the
superimposition of acute kidney injury compounded matters further.
Early renal pharmacotherapeutic research
and clinical practice was built upon the characterizations of renal elimination of an array
of drugs. Now, it is eminently clear that the
complex, aberrant biochemistry and inflammatory milieu of CKD and other states affect
the disposition of drugs in a multitude of
ways. Correspondingly, one key focus for research in pharmacotherapy of CKD will be
to develop a deeper appreciation of the alterations of metabolism of therapeutic and/or
potentially toxic agents. Such understanding
will ultimately yield critical knowledge regarding how these changes influence therapeutic efficacy and/or toxicity profiles. Such
insight will illuminate, at least in part, why
some drugs that are highly efficacious in the
general population are less effective, or not
at all effective, in patients with CKD. The
lack of efficacy of HMG-CoA reductase inhibitors in ESRD would be a point in this regard.
Or, is this an example of using a drug in a trial
wherein the drug would have not been anticipated to have an effect?
Problems with medication reconciliation
and adherence are plentiful in CKD patients,
particularly those with ESRD. This is hardly
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surprising given the pharmacopoeiac panoply
prescribed, which generally amounts to about
7 to 10 medications per individual.3 This number is easily achievable when one considers
CKD as a complex of disease domains including: (a) hypertension (2 or 3 drugs), (b) CKDmineral and bone disorder (1 or 2 drugs), (c)
metabolic acidosis (1 drug), (d) edema formation (1 or 2 drugs), (e) cardiovascular disease
prevention and treatment (1-5 drugs), (f) anemia of CKD (1-2 drugs), (g) diabetes (1-4
drugs), and (h) others. Moreover, the spectrum and number of agents sharply increase
in kidney allograft recipients and those suffering from HIV or AIDS, thus compounding the
problems of adherence, complications, and
drugedrug interactions. In the course of a visit
to the clinic, it is highly improbable that even
the best patient could recall all that was required of him or her regarding medication
changes and potential interactions.
Multiple risk factors, the most common of
which is a depressed GFR, predispose to
drug-induced kidney injury and/or disease.
These factors are under-appreciated and include patient-specific, kidney-related, and
drug-related factors that may synergize in
a pernicious promotion of damage to vulnerable kidneys.4 In addition, surreptitious druginduced kidney damage may accrue through
nontraditional acquisition of nephrotoxins,
for example, through the Internet. Contemporary and relevant examples of such damage
include the use of complementary medicines
or herbal remedies such as aristolochic acid
and adulterants like melamine.
Preventable events that induce or cause
inappropriate medication usage or harm the
patient, while a medication(s) is within the
control of the patient or the health care professional, constitute prescribing errors, according
to the National Coordinating Council for Medication Error Reporting and Prevention.5 To
comply with the Institute of Medicine’s recommendation to reduce medication errors
and mitigate hazardous drugedrug interactions, while facilitating and maintaining medication adherence, fully automated pharmacy
database systems with real-time medication

reconciliation must become the reality.6 Such
systems can preclude hazardous drug prescribing and interdict inadvertent drugedrug
interactions promptly, in a just-in-time 24/7/
365 manner. In addition, pro-active warning
systems must be incorporated and wholly
integrated into health care systems (and reforms) to provide greater patient safety during
the conduction of the multiple drug administration(s) that characterize the CKD patient
population.
In this issue, Guest Editors, Drs. Carol
Moore and Amy Barton Pai, provide to Advances in Chronic Kidney Disease its first ever
review of pharmacotherapy. Timely and precise updates regarding relevant issues in renal
pharmacotherapy have been judiciously selected to overview the state of the art involving drugs and the kidney. By the end of this
issue, one will even more greatly appreciate
the intelligence of the renal organs. Not simply confined to filtration function and master
balancer, and alchemist of electrolytes, divalent cations and “the acid and the alchaly,”
the kidneys metabolize drugs in a most profound manner. Nephrologists must appreciate
this. Thus, I concur with the charter of our cocaptains of the readership for this next-to-last
issue of 2010 and their informed heading.
Together with them, I say: “All Read Ahead.”
Jerry Yee, MD
Editor
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